About

Company History

Formed in 2015, TARGET PharmaSolutions was created as an outcome of the success of HCV-TARGET, a case study of the TARGET model in hepatitis C. HCV-TARGET was a partnership with academia, the FDA and industry established in 2011 by Dr. Michael Fried and Dr. David Nelson, which has enrolled 14,000+ patients at 60 sites in North America and Europe.

The evidence generated from HCV-TARGET has multiple applications, including being used by regulators to monitor post-marketing drug safety, by sponsors to support label expansion and to fulfill multiple post marketing commitments. In addition, it has helped inform national and international treatment guidelines, been used in payer dossiers, and has resulted in numerous high impact scientific presentations and publications.

To date, there have been over 31 publications of the HCV-TARGET data with over 90 unique authors.

at a glance:

  • Located in Durham, NC
  • 9 Leading Pharmaceutical Company Partnerships¬†
  • 200+ Community & Academic Sites
  • 6 Disease Communities¬†
  • 31 Publications with 70+ Unique Authors
  • Key Opinion Leaders on Academic & Publication Steering Committees

Company Timeline

2011

stacked books

HCV-Target

Feb. 2015

stacked books

TARGET PharmaSolutions founded

July 2016

stacked books

Launched NASH community

Oct. 2016

stacked books

Launched PBC community

Jan. 2017

stacked books

Launched HCC community

July 2017

stacked books

Launched IBD community

Nov. 2017

stacked books

Executed CRADA with FDA

Jan. 2018

stacked books

Site expansion in Europe

Aug. 2018

stacked books

Launched HBV community

Oct. 2018

stacked books

Launched DERM community